Examples of recent FDA excipient inspection findings and actions, describe FDA’s definition of excipients as “drug components” and review drug product/component adulteration provisions of the Food, Drug & Cosmetic Act. In addition, regulatory requirements for handling non-conformances, FDA’s expectations for investigations, and best-practice strategies (with examples and poll questions) for addressing corrective and preventative actions (CAPA) will be covered.